ALNYLAM PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Current
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Debt Securities, Available-for-sale, Current of $1.60 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-07-30
- 2026-06-30: Debt Securities, Available-for-sale, Current $1.60B.
- 2025-12-31: Debt Securities, Available-for-sale, Current $1.25B.
- 2025-09-30: Debt Securities, Available-for-sale, Current $1.23B.
- 2025-06-30: Debt Securities, Available-for-sale, Current $1.74B.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $1.60B 10-Q · filed 2026-07-30 |
| 2025-12-31 | $1.25B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.23B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $1.74B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $1.61B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.72B 10-K · filed 2026-02-12 |
| 2024-09-30 | $1.67B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.65B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.68B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.62B 10-K · filed 2025-02-13 |
| 2023-09-30 | $1.36B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.37B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.37B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.30B 10-K · filed 2024-02-15 |
| 2022-09-30 | $1.17B 10-Q · filed 2022-10-27 |
| 2022-06-30 | $1.50B 10-Q · filed 2022-07-28 |
| 2022-03-31 | $1.67B 10-Q · filed 2022-04-28 |
| 2021-12-31 | $1.55B 10-K · filed 2023-02-23 |
| 2021-09-30 | $1.16B 10-Q · filed 2021-10-28 |
| 2021-06-30 | $1.10B 10-Q · filed 2021-08-03 |
| 2021-03-31 | $1.27B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $1.33B 10-K · filed 2022-02-10 |
| 2020-09-30 | $1.28B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.26B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $836.35M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $975.02M 10-K · filed 2021-02-11 |
| 2019-09-30 | $797.75M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $790.54M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $519.58M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $662.80M 10-K · filed 2020-02-13 |
| 2018-09-30 | $905.22M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.07B 10-Q · filed 2018-08-02 |
| 2018-03-31 | $1.17B 10-Q · filed 2018-05-04 |
| 2017-12-31 | $1.05B 10-K · filed 2019-02-14 |
| 2017-09-30 | $746.25M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $514.60M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $385.84M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $424.19M 10-K · filed 2018-02-15 |
| 2016-09-30 | $531.04M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $571.99M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $748.42M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $848.22M 10-K · filed 2017-02-15 |
| 2015-09-30 | $828.43M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $788.74M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $660.40M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $526.93M 10-K · filed 2016-02-12 |
| 2014-09-30 | $507.93M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $524.59M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $314.90M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $192.70M 10-K · filed 2015-02-13 |
| 2013-09-30 | $181.94M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $184.72M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $138.21M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $71.41M 10-K · filed 2014-02-20 |
| 2012-09-30 | $152.50M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $180.75M 10-Q · filed 2012-08-08 |
| 2012-03-31 | $137.36M 10-Q · filed 2012-05-03 |
| 2011-12-31 | $76.17M 10-K · filed 2013-02-19 |
| 2011-09-30 | $98.69M 10-Q · filed 2011-11-03 |
| 2011-06-30 | $150.84M 10-Q · filed 2011-08-03 |
| 2011-03-31 | $154.05M 10-Q · filed 2011-05-05 |
| 2010-12-31 | $158.53M 10-K · filed 2012-02-13 |
| 2010-09-30 | $184.49M 10-Q · filed 2010-11-04 |
| 2010-06-30 | $193.01M 10-Q · filed 2010-08-05 |
| 2009-12-31 | $143.93M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |